The Botswana Medicines Regulatory Authority (BoMRA) and the South African Health Products Regulatory Authority (SAHPRA) have signed a memorandum of understanding (MoU) aimed at strengthening the regulation of medical products to safeguard public health in the two countries.
The partnership paves the way for the two regulators to collaborate and share information on the assessment of dossiers for medical products, which will result in efficiencies and commonality in the approval processes in both South Africa and Botswana.
The agreement also enables the parties to share information and build robust post-marketing monitoring and surveillance. it further presents for joint enforcement activities between SAHPRA and BoMRA This is especially crucial because South Africa plays an important role in the BoMRA value chain, with significant quantities of products originating from RSA or passing through its ports.
For his part, BoMRA Ag CEO Dr. Seima Dijeng, hailed SAHPRA as a s a very important strategic partner, the enduring relationship between Botswana and South Africa characterized by shared values, mutual respect, and ongoing economic cooperation. Therefore the Memorandum of Understanding (MoU) is a significant achievement in the journey of BoMRA
For her part, SAHPRA’s Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, said that the partnership is an important milestone in building capacity within the two regulators. It is also an opportunity to ensure robust intra-country post-marketing safety monitoring of health products and sharing of data that will lead to more vigorous monitoring of products once they are in the market.
BoMRA derives its mandate from the Medicines and Related Substances Act (MRSA of 2013), to regulate human and veterinary medicines, medical devices , cosmetics and complementary medicines to ensure that they conform to the set standards of safety, quality and efficacy.
SAHPRA on the other hand regulates (monitors, evaluates, investigates, inspects and registers) all health products. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, the Authority is responsible for overseeing radiation control in South Africa. Its mandate is outlined in the Medicines and Related Substances Act, 101 of 1965 (as amended), as well as the Hazardous Substances Act, 15 of 1973.